Lung cancer has traditionally been associated with advanced age; however, its increasing
incidence among young adults raises concerning questions regarding its etiology and …

Methods Herein, we defined vulnerable as the group of patients with NSCLC and
performance status (PS)≥ 2 (poor PS), advanced age (≥ 75 years), or cancer cachexia. We …

Immune checkpoint inhibitors (ICIs) have improved the long-term survival of NSCLC
patients. However, the efficacy of ICIs in elderly NSCLC patients remains controversial. We …

Background The understanding of the factors causing decreased overall survival (OS) in
older patients compared to younger patients in lung adenocarcinoma (LUAD) remains …

The older American population is rapidly increasing, and millions of older adults will be
cancer survivors with comorbidities. This population faces specific challenges regarding …

Abstract Purpose of Review This manuscript will update prior reviews of immune checkpoint
inhibitors (ICIs) in light of basic science, translational, and clinical discoveries in the field of …

The adoption of immune checkpoint inhibitors (ICIs) over the past decade has drastically
changed the treatment paradigm of non–small cell lung cancer (NSCLC). The novel …

Introduction Only a few reports have determined whether recently advanced anticancer
drugs, particularly next-generation tyrosine kinase inhibitors (TKIs) and immune checkpoint …

Background: For eligible patients with unresectable stage III non-small-cell lung cancer,
durvalumab consolidation therapy following chemoradiotherapy is the standard of care …

Background Despite major advances in cancer therapeutics, the therapeutic options of Lung
Squamous Cell Carcinoma (LSCC)-specific remain limited. Furthermore, the current staging …